KairosHelix published a case study on the rapid optimization of a KRAS-PDAC clinical trial design.

Overview: Kairos. The decisive moment. Helix. The structure that preserves intelligence across generations. Clinical development has mastered execution. It has not mastered learning. Every clinical trial generates critical intelligence about what works, what fails, where patients are found, and which decisions create delay. That intelligence is captured, archived, and rarely applied to the next study. KairosHelix exists to ensure it does not. Our Vision: Clinical development should not forget. Trials are executed as isolated events. Knowledge is fragmented across documents, teams, and systems, and rarely reused to improve future decisions. The same patterns and avoidable delays repeat. We believe clinical development should function as a compounding system, where every study strengthens the next and decisions are informed by what has already been learned. Our Mission: KairosHelix is building a new intelligence layer for clinical development. This layer captures, connects, and applies trial knowledge across the lifecycle, enabling teams to move from isolated execution to continuous learning and from reactive decisions to predictive, evidence-driven guidance. Our mission is to reduce avoidable delays, improve decision quality, and compress the time between protocol and patient. Our Company: KairosHelix is an AI native platform designed to bring compounding intelligence to clinical development. It operates as a non disruptive layer over existing systems, requiring no migration and preserving full data sovereignty. Rather than replacing infrastructure, it unlocks the intelligence already embedded within it. By structuring and connecting clinical knowledge across studies, KairosHelix enables earlier pattern detection, better decisions, and continuous improvement in how trials are designed and executed. The platform is being developed in stealth in collaboration with industry leaders.